VKTX vs. PRTA, ICPT, PBYI, MRNS, TEVA, GMAB, RPRX, BMRN, BGNE, and UTHR
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Prothena (PRTA), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI), Marinus Pharmaceuticals (MRNS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), and United Therapeutics (UTHR).
Prothena (NASDAQ:PRTA) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Prothena currently has a consensus target price of $66.00, suggesting a potential upside of 170.16%. Viking Therapeutics has a consensus target price of $111.78, suggesting a potential upside of 69.41%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Prothena is more favorable than Viking Therapeutics.
97.1% of Prothena shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 28.2% of Prothena shares are owned by insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -193.17%. Prothena's return on equity of -17.58% beat Viking Therapeutics' return on equity.
In the previous week, Viking Therapeutics had 35 more articles in the media than Prothena. MarketBeat recorded 40 mentions for Viking Therapeutics and 5 mentions for Prothena. Viking Therapeutics' average media sentiment score of 1.17 beat Prothena's score of 0.73 indicating that Prothena is being referred to more favorably in the media.
Viking Therapeutics received 7 more outperform votes than Prothena when rated by MarketBeat users. Likewise, 79.87% of users gave Viking Therapeutics an outperform vote while only 70.59% of users gave Prothena an outperform vote.
Prothena has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Viking Therapeutics has lower revenue, but higher earnings than Prothena. Viking Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Summary
Viking Therapeutics beats Prothena on 12 of the 18 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
